|
Market Closed -
Other stock markets
|
After market 04:57:52 pm | |||
| 101.4 USD | -0.58% |
|
101.5 | +0.05% |
| 07:26am | China's drugmakers can't sell mRNA shots but haven't quit yet | RE |
| Apr. 16 | Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing | MT |
(Reuters) - Novavax Inc cut its full-year revenue forecast on Tuesday, hurt by a global supply glut in COVID-19 vaccine and waning demand.
The company now expects annual revenue to be about $2 billion, the lower end of its prior forecast range of between $2 billion and $2.3 billion.
In August, Novavax halved its full-year revenue forecast as it did not expect further sales of its COVID-19 shot this year in the United States.
Novavax said its vaccine brought $626.1 million in product sales in the third quarter, as the company sold 35 million doses globally.
(Reporting by Raghav Mahobe in Bengaluru; Editing by Maju Samuel)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.97% | 39.05B | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B | |
| -19.49% | 9.78B |
MODERNA, INC. 
